Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer

The Prostate ◽  
2012 ◽  
Vol 73 (5) ◽  
pp. 512-521 ◽  
Author(s):  
Jordi Codony-Servat ◽  
Mercedes Marín-Aguilera ◽  
Laura Visa ◽  
Xabier García-Albéniz ◽  
Estela Pineda ◽  
...  
2012 ◽  
Vol 10 (2) ◽  
pp. 91-99 ◽  
Author(s):  
Pamela McCall ◽  
Jamie Catlow ◽  
Peter A McArdle ◽  
Donald C McMillan ◽  
Joanne Edwards

2010 ◽  
Vol 110 (2) ◽  
pp. 312-320 ◽  
Author(s):  
Bettina Jungwirth ◽  
Barbara Eckel ◽  
Manfred Blobner ◽  
Kristine Kellermann ◽  
Eberhard F. Kochs ◽  
...  

2009 ◽  
Vol 124 (2) ◽  
pp. 494-501 ◽  
Author(s):  
Alison M. Karst ◽  
Kai Gao ◽  
Colleen C. Nelson ◽  
Gang Li

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 80-80
Author(s):  
Fred Saad ◽  
Veronique Ouellet ◽  
Andree-Anne Grosset ◽  
Christine Caron ◽  
Veronique Barres ◽  
...  

80 Background: The CPCBN has assembled a TMA-based resource comprising the specimens of 1512 prostate cancer patients treated by radical prostatectomy. This richly annotated and multi-institutional resource is available to researchers who wish to access a large cohort to validate prognostic biomarkers (http://www.tfri.ca/en/research/translational-research/cpcbn.aspx). Over the last decade, our laboratory demonstrated with an independent cohort (Gannon PO, et al. Eur J Cancer. 2013 Jul;49(10):2441-8, Labouba I, et al. PLoS One. 2015 Jul 17;10(7):e0131024), the reproducible association of nuclear factor-kappa B (NF-kB) p65 with patient’s risk of biochemical recurrence. Here, we evaluated the CPCBN TMA-series for p65 expression. Methods: Two independent observers scored the frequency of p65 nuclear localisation on digital images obtained after automated immunohistochemistry analysis of p65. Over the available minimum 3 cores of tumour tissue per patient, an average percentage of positive nucleus frequency was used. Statistical analyses were performed using SPSS software. Results: High nuclear frequency of NF-kB p65 (cut-off at 3%) was associated with an increased risk for patients to experience a biochemical relapse (p < 0.001; Exp(B) = 1.599; 95%CI = 1.321-1.937), develop bone metastasis (p = 0.007; Exp(B) = 2.126; 95%CI = 1.234-3.663)and die from their disease (p = 0.001; Exp(B) = 3.117; 95%CI = 1.55-6.266). In multivariate analyses, p65 also remained independent from clinical parameters (PSA, Gleason score and pTNM): biochemical relapse (p = 0.005; Exp(B) = 1.331; 95%CI = 1.092-1.623), bone metastasis (p = 0.033; Exp(B) = 1.82; 95%CI = 1.04- 3.158), mortality (p = 0.007; Exp(B) = 2.626; 95%CI = 1.298-5.312) Conclusions: Using a large cohort of Canadian men, our study reiterates the previous study linking NF-kB p65 with prostate cancer progression and highlights the suitability of CPCBN TMAs for biomarker validation. Our results also reveal the role of p65 as a predictor of bone metastasis development and prostate cancer-specific mortality.


Author(s):  
William Browder ◽  
Tuanzhu Ha ◽  
Chuanfu Li ◽  
John H. Kalbfleisch ◽  
Donald A. Ferguson ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document